Uncovering Institutional Buying In Recursion Pharmaceuticals Inc (NASDAQ: RXRX)

Currently, there are 226.26M common shares owned by the public and among those 146.54M shares have been available to trade.

However, the script later moved the day high at 9.97, down -6.02%. The company’s stock has a 5-day price change of -10.68% and -11.69% over the past three months. RXRX shares are trading -4.97% year to date (YTD), with the 12-month market performance up to 38.81% higher. It has a 12-month low price of $4.54 and touched a high of $16.75 over the same period. RXRX has an average intraday trading volume of 7.14 million shares. The stock is trading above its simple moving averages at the SMA20, SMA50, and SMA200, as the current price level is off by -14.79%, -15.55%, and 0.49% respectively.

Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.

Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!

Get the FREE Report with all the details here.


Institutional ownership of Recursion Pharmaceuticals Inc (NASDAQ: RXRX) shares accounts for 77.29% of the company’s 226.26M shares outstanding.

It has a market capitalization of $2.02B and a beta (3y monthly) value of 0.75. The earnings-per-share (ttm) stands at -$1.55. Price movements for the stock have been influenced by the stock’s volatility, which stands at 4.86% over the week and 8.03% over the month.

Analysts forecast that Recursion Pharmaceuticals Inc (RXRX) will achieve an EPS of -$0.42 for the current quarter, -$0.42 for the next quarter and -$1.86 for 2025. The lowest estimate earnings-per-share for the quarter is -$0.46 while analysts give the company a high EPS estimate of -$0.39. Comparatively, EPS for the current quarter was -$0.34 a year ago. Earnings per share for the fiscal year are expected to decrease by -9.14%, and -7.82% over the next financial year. EPS should grow at an annualized rate of 12.00% over the next five years, compared to -43.41% over the past 5-year period.

Looking at the support for the RXRX, a number of firms have released research notes about the stock. Morgan Stanley stated their Equal-Weight rating for the stock in a research note on May 22, 2023, with the firm’s price target at $8. Needham coverage for the Recursion Pharmaceuticals Inc (RXRX) stock in a research note released on March 16, 2023 offered a Buy rating with a price target of $17. KeyBanc Capital Markets was of a view on September 16, 2022 that the stock is Overweight, while BofA Securities gave the stock Neutral rating on April 18, 2022, issuing a price target of $10. SVB Leerink on their part issued Mkt Perform rating on March 04, 2022.

Most Popular

Related Posts